COMMUNIQUÉS West-GlobeNewswire

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
26/01/2024
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024 Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional [...]
ArriVent Announces Pricing of Upsized Initial Public Offering
26/01/2024
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical [...]
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
26/01/2024
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to [...]
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
26/01/2024
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
25/01/2024
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a [...]
ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)
25/01/2024
Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual Meeting EINDHOVEN, the Netherlands, Jan. 25, 2024 (GLOBE NEWSWIRE) -- ONWARD [...]
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
25/01/2024
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The [...]
CooperCompanies Announces Release Date for First Quarter 2024
25/01/2024
SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024 financial results on Thursday, February 29, 2024, at 4:15 PM ET. Following the release [...]
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
25/01/2024
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx [...]
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25/01/2024
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients [...]
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
25/01/2024
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics [...]
Introducing cutting-edge features to transform the dental experience: PreVu Software unveils AI-powered enhancements for smile simulation software
25/01/2024
FORT LAUDERDALE, FLA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PreVu Software, a pioneer in dental technology solutions, proudly announces the launch of new, innovative technology that will continue our tradition of delivering [...]
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
25/01/2024
Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children [...]
Communiqué de presse : Dupixent® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois
25/01/2024
Dupixent ® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Approbation fondée sur les résultats de l’essai de phase III EoE KIDS ayant [...]
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25/01/2024
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
25/01/2024
Company Announcement COPENHAGEN, Denmark; January 25, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of the Company and the [...]
Confluent Announces Significant Investment in ATI Nitinol Melt Expansion
25/01/2024
Confluent Becomes ATI’s Fulfillment Partner for Medical Nitinol SCOTTSDALE, Ariz., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more [...]
Renovaro Biosciences Announces Results of Special Meeting of Shareholders
25/01/2024
LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’ [...]
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25/01/2024
License allows PharmAla to drive revenue and growth while remaining true to its “regulatory first” mission VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or [...]

Pages